Capricor Therapeutics to Present One-Year Results from HOPE-2 Open Label Extension Study at World Muscle Society 2022
October 06, 2022 09:00 ET
|
Capricor Therapeutics
SAN DIEGO, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR) a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the...
Capricor Therapeutics to Present at Upcoming Investor Conferences
September 07, 2022 08:00 ET
|
Capricor Therapeutics
SAN DIEGO, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR) a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the...
Capricor Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update
August 10, 2022 16:05 ET
|
Capricor Therapeutics
-First Patient Treated in HOPE-3, the Pivotal Phase 3 Clinical Trial of CAP-1002 in Duchenne Muscular Dystrophy- -Positive One-Year Safety and Efficacy Results From HOPE-2 Open...
Capricor Therapeutics to Present Second Quarter 2022 Financial Results and Recent Corporate Update on August 10
August 03, 2022 08:00 ET
|
Capricor Therapeutics
SAN DIEGO, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the...
Capricor Therapeutics Announces First Patient Dosed in Pivotal Phase 3 Study of CAP-1002 for the Treatment of Duchenne Muscular Dystrophy
July 19, 2022 09:15 ET
|
Capricor Therapeutics
-Double-Blind, Randomized, Placebo-Controlled HOPE-3 Clinical Trial Designed to Enroll approximately 70 Patients- -HOPE-3 Builds on Positive Data Results from HOPE-2 Study Recently Published in The...
Capricor Therapeutics Announces Statistically Significant Clinical Benefits in Skeletal Muscle Function in Non-Ambulant Duchenne Muscular Dystrophy Patients Treated with CAP-1002 in HOPE-2 Open Label Extension Study
June 27, 2022 07:00 ET
|
Capricor Therapeutics
-Met Primary Endpoint of Performance of the Upper Limb PUL 2.0 (p=0.02)- -Results Suggest Disease Modification in DMD and Long-term Safety of CAP-1002- -Results were Presented at Late Breaking...
Capricor Therapeutics to Present One-Year Efficacy Results from its Ongoing HOPE-2 Open Label Extension Study at 2022 Parent Project Muscular Dystrophy Annual Conference
June 17, 2022 09:00 ET
|
Capricor Therapeutics
SAN DIEGO, June 17, 2022 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the...
Capricor Therapeutics Appoints Xavier Avat as Chief Business Officer
May 25, 2022 09:00 ET
|
Capricor Therapeutics
Capricor Expands Senior Management Team to Build Commercial Strategy for Lead Asset, CAP-1002, and Further Develop Partnering Strategy for Proprietary Exosome Platform Formerly at Edwards...
Capricor Therapeutics to Present at the H.C. Wainwright Global Investment Conference
May 18, 2022 09:00 ET
|
Capricor Therapeutics
SAN DIEGO, May 18, 2022 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the...
Capricor Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update
May 10, 2022 16:01 ET
|
Capricor Therapeutics
-Executed Partnership with Nippon Shinyaku for the Commercialization and Distribution of CAP-1002 for Duchenne Muscular Dystrophy in the United States- -Upfront Payment of $30 Million Received in...